Influence of fatty acid metabolism for clinical course of biliary atresia

The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041180088

Enrollment

Registered

2019-03-12

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.

Interventions

oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) New case with biliary atresia. 2) As control group A, cases of suspected biliary atresia with liver dysfunction or jaundice. 3) As control group B, healthy individuals with similar age.

Exclusion criteria

Exclusion criteria: A history of blood transfusion within 1 month before enrollment

Design outcomes

Primary

Measure	Time frame
Liver fibrosis in BA patients with or without administration of EPA	—

Secondary

Measure	Time frame
The difference of concentration of long chain polyunsaturated fatty acids, or eicosanoids among BA group and non-BA groups	—

Contacts

Public ContactWataru Sumida

Nagoya University Hospital

wsumida@med.nagoya-u.ac.jp+81-52-744-2959

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026